Transcatheter Mitral Valve Replacement with Dedicated Devices

Joe Aoun; Michael J. Reardon; Sachin S. Goel

doi:10.14797/mdcvj.1231

Transcatheter Mitral Valve Replacement with Dedicated Devices

Methodist DeBakey Cardiovascular Journal

Volume 19 (2023): Issue 3

By: Joe Aoun , Michael J. Reardon and Sachin S. Goel

Open Access

|May 2023

Abstract

Mitral regurgitation is the most common form of valvular heart disease. The anatomy and pathophysiology of mitral valve regurgitation are very complex, and dedicated devices are required for transcatheter mitral valve replacement in patients with a high or prohibitive surgical risk. In the United States, all transcatheter mitral valve replacement devices are still being studied and are not yet approved for commercial use. Early feasibility studies have demonstrated good technical success and short-term outcomes, but larger samples and longer-term outcomes still need to be assessed. Furthermore, significant advances in device technology, delivery systems, and implantation techniques are essential to avoid left ventricular outflow tract obstruction, and valvular and paravalvular regurgitation as well as ensuring good anchoring of the prosthesis.

References

Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014 Jan 21;63(2):185–6. doi: 10.1016/j.jacc.2013.08.723
Open DOI Search in Google Scholar Back to article
Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007 Jun;28(11):1358–65. doi: 10.1093/eurheartj/ehm001
Open DOI Search in Google Scholar Back to article
Grinberg D, Pozzi M, Bernard C, Obadia JF. A tensed Tendyne. Eur J Cardiothorac Surg. 2020 Sep 1;58(3):651–653. doi: 10.1093/ejcts/ezaa109
Open DOI Search in Google Scholar Back to article
Aktuerk D, Jansz P, Shaw M, Muller DWM. Successful repositioning of apically tethered transcatheter mitral valve replacement in the off-bypass, beating heart. Catheter Cardiovasc Interv. 2020 Jan;95(1):E37–E39. doi: 10.1002/ccd.28210
Open DOI Search in Google Scholar Back to article
Badhwar V, Sorajja P, Duncan A, et al. Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation. EuroIntervention. 2019 Dec 20;15(12):e1065–e1071. doi: 10.4244/EIJ-D-19-00333
Open DOI Search in Google Scholar Back to article
Muller DWM, Sorajja P, Duncan A, et al. 2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation. J Am Coll Cardiol. 2021 Nov 9;78(19):1847–1859. doi: 10.1016/j.jacc.2021.08.060
Open DOI Search in Google Scholar Back to article
Muller DWM, Farivar RS, Jansz P, et al. Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A Global Feasibility Trial. J Am Coll Cardiol. 2017 Jan 31;69(4):381–391. doi: 10.1016/j.jacc.2016.10.068
Open DOI Search in Google Scholar Back to article
Sorajja P, Moat N, Badhwar V, et al. Initial Feasibility Study of a New Transcatheter Mitral Prosthesis: The First 100 Patients. J Am Coll Cardiol. 2019 Mar 26;73(11):1250–1260. doi: 10.1016/j.jacc.2018.12.066
Open DOI Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT); 2023 Mar 23 [cited 2023 Apr 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03433274
Search in Google Scholar Back to article
McCarthy PM, Kislitsina ON, Malaisrie SC, Davidson CJ. Transcatheter Mitral Valve Replacement with Intrepid. Interv Cardiol Clin. 2019 Jul;8(3):287–294. doi: 10.1016/j.iccl.2019.02.002
Open DOI Search in Google Scholar Back to article
Bapat V, Rajagopal V, Meduri C, et al. Early Experience With New Transcatheter Mitral Valve Replacement. J Am Coll Cardiol. 2018 Jan 2;71(1):12–21. doi: 10.1016/j.jacc.2017.10.061
Open DOI Search in Google Scholar Back to article
Zahr F, Song HK, Chadderdon SM, et al. 30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results. JACC Cardiovasc Interv. 2022 Jan 10;15(1):80–89. doi: 10.1016/j.jcin.2021.10.018
Open DOI Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) ; 2018 Nov [cited 2023 Apr 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT01960348
Search in Google Scholar Back to article
Nunes Ferreira-Neto A, Dagenais F, Bernier M, Dumont E, Freitas-Ferraz AB, Rodés-Cabau J. Transcatheter Mitral Valve Replacement With a New Supra-Annular Valve: First-in-Human Experience With the AltaValve System. JACC Cardiovasc Interv. 2019 Jan 28;12(2):208–209. doi: 10.1016/j.jcin.2018.10.056
Open DOI Search in Google Scholar Back to article
Goel SS, Zuck V, Christy J, et al. Transcatheter Mitral Valve Therapy With Novel Supra-Annular AltaValve: First Experience in the United States. JACC Case Rep. 2019 Dec 18;1(5):761–764. doi: 10.1016/j.jaccas.2019.10.034
Open DOI Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Early Feasibility Study of the Neovasc Tiara^TM Mitral Valve System (TIARA-I); 2022 Jan 18 [cited 2023 Apr 25]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02276547
Search in Google Scholar Back to article
Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous Transcatheter Mitral Valve Replacement: First-in-Human Experience With a New Transseptal System. J Am Coll Cardiol. 2019 Mar 26;73(11):1239–1246. doi: 10.1016/j.jacc.2018.12.065
Open DOI Search in Google Scholar Back to article
Makkar R, O’Neill W, Whisenant B, et al. Updated 30-Day Outcomes for the U.S. Early Feasibility Study of the SAPIEN M3 Transcatheter Mitral Valve Replacement System. J Am Coll Cardiol. 2019 Sep 1;74(13):B8.
Search in Google Scholar Back to article
Webb J, Hensey M, Fam N, et al. Transcatheter Mitral Valve Replacement With the Transseptal EVOQUE System. JACC Cardiovasc Interv. 2020 Oct 26;13(20):2418–2426. doi: 10.1016/j.jcin.2020.06.040
Open DOI Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Edwards EVOQUE Eos MISCEND Study; 2023 Jan 23 [cited 2023 Apr 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02718001
Search in Google Scholar Back to article
Alperi A, Dagenais F, Del Val D, et al. Early Experience With a Novel Transfemoral Mitral Valve Implantation System in Complex Degenerative Mitral Regurgitation. JACC Cardiovasc Interv. 2020 Oct 26;13(20):2427–2437. doi: 10.1016/j.jcin.2020.08.006
Open DOI Search in Google Scholar Back to article
Modine T, Vahl TP, Khalique OK, et al. First-in-Human Implant of the Cephea Transseptal Mitral Valve Replacement System. Circ Cardiovasc Interv. 2019 Sep;12(9):e008003. doi: 10.1161/CIRCINTERVENTIONS.119.008003
Open DOI Search in Google Scholar Back to article
Rottbauer W, Schneider L, Nickenig G, et al. TCT-191 HighLife Trans-Septal Mitral Valve Replacement (TSMVR) System; Early and Long Term Clinical and Hemodynamic Outcomes of the First 30 Consecutive Cases; The HighLife Feasibility Studies in Europe, Australia, and the US. J Am Coll Cardiol. 2021 Nov 9;78(19_Supplement_S):B78–9.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. HighLife^TM Transcatheter Mitral Valve Replacement System Study; 2022 Sep 15 [cited 2023 Apr 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02974881
Search in Google Scholar Back to article
Innovalvemed.com [Internet]. Ramat Gan, Israel; c2023. Our Technology; 2023 [cited 2023 Apr 25]. Available from: https://www.innovalvemed.com/technology/
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. TVMR With the Innovalve System Trial - Early Feasibility Study (TWIST-ESF); 2022 Dec 23 [cited 2023 Apr 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04919980
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcvj.1231 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 50 - 56

Submitted on: Mar 19, 2023

Accepted on: Apr 26, 2023

Published on: May 16, 2023

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

mitral regurgitation,

transcatheter mitral valve replacement,

Tendyne,

Intrepid,

Sapien valve

© 2023 Joe Aoun, Michael J. Reardon, Sachin S. Goel, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 19 (2023): Issue 3